Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.

doi:10.1186/s13014-023-02218-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.

Radiation oncology (London, England) - 7 Feb 2023

Higaki Hajime, Nishioka Kentaro, Otsuka Manami, Nishikawa Noboru, Shido Motoyasu, Minatogawa Hideki, Nishikawa Yukiko, Takashina Rikiya, Hashimoto Takayuki, Katoh Norio, Taguchi Hiroshi, Kinoshita Rumiko, Yasuda Koichi, Mori Takashi, Uchinami Yusuke, Koizumi Fuki, Fujita Yoshihiro, Takahashi Shuhei, Hattori Takahiro, Nishiyama Noriaki, Aoyama Hidefumi

Abstract excerpt

BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to East Asian People

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 36750899
DOI: 10.1186/s13014-023-02218-3
PMCID: PMC9903535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.PMID 36750899Read ↗

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors: a retrospective studySemantic proximity Read ↗

Evaluation of the Updated 2022 Lung-GPA in NSCLC Adenocarcinoma Patients with Brain Metastases: Analysis of Prognostic Factors in a German Clinical CohortSemantic proximity Read ↗

Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.Semantic proximity Read ↗

Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.Semantic proximity Read ↗

Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Survival and prognostic factors in non-small cell lung cancer patients with brain metastases limited access to systemic therapySemantic proximity Read ↗

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis.Semantic proximity Read ↗

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.Semantic proximity Read ↗

The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain MetastasesSemantic proximity Read ↗

The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.Semantic proximity Read ↗

The Optimal Therapeutic Strategy for Patients with EGFR-Mutated Non–Small Cell Lung Cancer with Brain Metastasis: A Real-World Study from TaiwanSemantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.